Targeting adenosine A2A receptor antagonism for treatment of cancer

ABSTRACT Introduction: Adenosine A2A Receptor (A2AR) antagonists are an emerging class of agents that treat cancers, both as a monotherapy and in combination with other therapeutic agents. Several studies support the accumulation of extracellular adenosine in the tumor microenvironment as a critical mechanism in immune evasion implicating A2AR antagonists for use in immuno-oncology. Areas covered: In this perspective article, the authors briefly outline the history of the A2AR antagonist field for central nervous system indications and give their perspective on the status of agents progressing today in oncology. A brief description of the biological rationale in oncology is given. A particular focus of this article is progress in A2AR structure determination and its impact on Structure-Based Drug Design. Expert opinion: Our understanding of the A2AR antagonist mechanism of action has changed and is now being clinically validated by several key companies in the oncology field. This area is likely to rapidly develop over the next 1–2 years.

[1]  Francesca Deflorian,et al.  High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks , 2013, In Silico Pharmacology.

[2]  S. Loi,et al.  Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors , 2017 .

[3]  S. Antonia,et al.  A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment , 2017, Neoplasia.

[4]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[5]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[6]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[7]  Ruben Abagyan,et al.  Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. , 2012, Journal of medicinal chemistry.

[8]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[9]  David M. Conrad,et al.  Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). , 2008, International journal of oncology.

[10]  M. Smyth,et al.  Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.

[11]  J. Linden,et al.  Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. , 2014, Cancer research.

[12]  Stefano Moro,et al.  Bridging Molecular Docking to Membrane Molecular Dynamics To Investigate GPCR-Ligand Recognition: The Human A2A Adenosine Receptor as a Key Study , 2014, J. Chem. Inf. Model..

[13]  B. Shook,et al.  Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. , 2011, ACS chemical neuroscience.

[14]  E. Morris,et al.  Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. , 2018 .

[15]  Stephen P. H. Alexander,et al.  [3H]ZM241385—an antagonist radioligand for adenosine A2A receptors in rat brain , 2001 .

[16]  B. Neustadt,et al.  Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.

[17]  N. Wald,et al.  Abstract LB-291: EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics , 2018 .

[18]  R. Hodgson,et al.  Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. , 2010, Current opinion in drug discovery & development.

[19]  S. Loi,et al.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.

[20]  Andrzej J. Bojarski,et al.  Impact of Template Choice on Homology Model Efficiency in Virtual Screening , 2014, J. Chem. Inf. Model..

[21]  Neha Singh,et al.  Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.

[22]  L. Grégoire,et al.  Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders , 2010, Experimental Neurology.

[23]  Andrew S Doré,et al.  Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals , 2018, Scientific Reports.

[24]  M. Idzko,et al.  Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. , 2003, Blood.

[25]  D. Carbone,et al.  Adenosine receptors in regulation of dendritic cell differentiation and function. , 2008, Blood.

[26]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[27]  Jiayu Wen,et al.  Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models , 2018, Cancer Immunology, Immunotherapy.

[28]  Stephen P. H. Alexander,et al.  [(3)H]ZM241385--an antagonist radioligand for adenosine A(2A) receptors in rat brain. , 2001, European Journal of Pharmacology.

[29]  M. Curran,et al.  Regadenoson , 2010, American Journal of Cardiovascular Drugs.

[30]  M. Smyth,et al.  CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.

[31]  R. Hollingsworth,et al.  Targeting CD73 in the tumor microenvironment with MEDI9447 , 2016, Oncoimmunology.

[32]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[33]  T. Ceska,et al.  Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket , 2017, Proceedings of the National Academy of Sciences.

[34]  Catarina Gomes,et al.  Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. , 2011, Biochimica et biophysica acta.

[35]  Ali Jazayeri,et al.  Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. , 2017, Chemical reviews.

[36]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[37]  Manuel de Lera Ruiz,et al.  Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.

[38]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[39]  S. P. Andrews,et al.  Structure-based drug design of chromone antagonists of the adenosine A2A receptor , 2014 .

[40]  J. Åqvist,et al.  Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors , 2017, Molecules.

[41]  G. Marucci,et al.  Adenosine receptor modeling: what does the A2A crystal structure tell us? , 2010, Current topics in medicinal chemistry.

[42]  J. Powell,et al.  Adenosine and anergy , 2007, Autoimmunity.

[43]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[44]  Fei Xu,et al.  Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. , 2012, Journal of medicinal chemistry.

[45]  C. Tate,et al.  Expression, Purification and Crystallisation of the Adenosine A2A Receptor Bound to an Engineered Mini G Protein. , 2017, Bio-protocol.

[46]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[47]  Deborah S. Barkauskas,et al.  Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. , 2016, Cancer research.

[48]  Gregg Siegal,et al.  Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.

[49]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[50]  K. Fuxe,et al.  Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. , 2005, Life sciences.

[51]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[52]  B. Schraven,et al.  Adenosine regulates CD8 T‐cell priming by inhibition of membrane‐proximal T‐cell receptor signalling , 2009, Immunology.

[53]  Christopher G Tate,et al.  Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein , 2018, bioRxiv.

[54]  S. P. Andrews,et al.  Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor , 2013 .

[55]  C. Müller,et al.  Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor. , 2017, Angewandte Chemie.

[56]  Deborah S. Barkauskas,et al.  Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. , 2016, Cancer cell.

[57]  Nathan Robertson,et al.  Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.

[58]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[59]  U. Schindler,et al.  Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy , 2018, Immunology.

[60]  Jonathan W. Essex,et al.  Water Network Perturbation in Ligand Binding: Adenosine A2A Antagonists as a Case Study , 2013, J. Chem. Inf. Model..

[61]  J. Errey,et al.  Biacore analysis with stabilized G-protein-coupled receptors. , 2011, Analytical biochemistry.

[62]  E. Deeks,et al.  Istradefylline: First Global Approval , 2013, Drugs.

[63]  A. Leslie,et al.  Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor , 2015, Molecular Pharmacology.

[64]  Ruben Abagyan,et al.  Structure based prediction of subtype-selectivity for adenosine receptor antagonists , 2011, Neuropharmacology.

[65]  A. Hotson,et al.  Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1 , 2016 .

[66]  E. Dmitrovsky,et al.  CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. , 2018, Cancer discovery.

[67]  James D. Clarke,et al.  Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression , 2017 .

[68]  Hugo Gutiérrez-de-Terán,et al.  Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists , 2012, Journal of Computer-Aided Molecular Design.

[69]  Yitian Chen,et al.  Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. , 2013, World journal of gastroenterology.

[70]  Enabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor , 2018, Scientific Reports.

[71]  A. Leslie,et al.  Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.

[72]  K. Varani,et al.  History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents , 2015, Medicinal research reviews.

[73]  S. Iwata,et al.  G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.

[74]  C. Higgs,et al.  Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.

[75]  A. Ohta,et al.  The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway , 2012, Front. Immun..

[76]  Andrea Bortolato,et al.  New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[77]  R. Franco,et al.  Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges , 2018, Front. Psychiatry.

[78]  Jonathan S. Mason,et al.  Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.

[79]  J. Schrader,et al.  Turnover of adenosine in plasma of human and dog blood. , 1989, The American journal of physiology.

[80]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[81]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[82]  Deborah S. Barkauskas,et al.  A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. , 2018, Cancer research.

[83]  Deborah S. Barkauskas,et al.  Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases , 2017, Oncoimmunology.

[84]  J. Blay,et al.  The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.

[85]  Xiaojian Wu,et al.  High expression of CD73 as a poor prognostic biomarker in human colorectal cancer , 2012, Journal of surgical oncology.